Much about post-acute COVID syndromes remains ‘poorly defined’

Despite a growing body of evidence documenting the existence of post-acute COVID-19 syndromes, there remain many more questions than answers, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.
Leonard Calabrese, DO, RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic, covered long COVID — also called “long-haulers” or post-acute sequelae of COVID-19 (PASC) — from “30,000 feet” in his presentation. The talk covered epidemiology, major endotypes, pathogenesis and emerging therapies.
Data on this

Despite a growing body of evidence documenting the existence of post-acute COVID-19 syndromes, there remain many more questions than answers, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.
Leonard Calabrese, DO, RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic, covered long COVID — also called “long-haulers” or post-acute sequelae of COVID-19 (PASC) — from “30,000 feet” in his presentation. The talk covered epidemiology, major endotypes, pathogenesis and emerging therapies.
Data on this